New treatment to slow muscle weakening in Duchenne muscular dystrophy
Official title: Development of a Novel Calcium Channel Therapeutic for Dystrophinopathies
Funded at Vivreon Biosciences, LLC · NIH-10921411 · Data updated 2026-11-12
This study is testing a new treatment that aims to help people with Duchenne muscular dystrophy (DMD) by improving how their muscle cells handle calcium, which could slow down muscle weakness and damage.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vivreon Biosciences, LLC NIH-funded |
| Lab location | 1 site (San Diego, UNITED STATES) |
| Project start | September 1, 2024 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $306,872 |
| NIH project number | 1R43AR083315-01A1 |
| Project ID | NIH-10921411 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Duchenne muscular dystrophy or related dystrophinopathies.
✕Less likely to help
Patients with other forms of muscular dystrophy or those without a diagnosis of dystrophinopathies may not benefit from this research.
What this research studies
This research focuses on developing a novel small molecule therapeutic that targets calcium channels to help delay the muscle weakening associated with dystrophinopathies, particularly Duchenne muscular dystrophy (DMD). The approach involves modulating the Orai1 calcium channel, which has been shown to contribute to muscle damage in preclinical models. By improving calcium handling in muscle cells, the treatment aims to reduce inflammation and muscle degeneration. Patients may be monitored for improvements in muscle strength and function as part of this innovative therapeutic strategy.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option that slows the progression of muscle weakness in patients with Duchenne muscular dystrophy.
How similar studies have gone: This approach is based on promising preclinical findings, suggesting that targeting the Orai1 calcium channel may effectively mitigate muscle degeneration, although it is still in the early stages of clinical application.
Where this research is happening
-
Vivreon Biosciences, LLC
San Diego, United States Active
Researchers
- Principal investigator: Greenberg, Milton L — Vivreon Biosciences, LLC
- Study coordinator: Greenberg, Milton L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.